NBC Scores Ratings Hit With Kentucky Derby Broadcast

Medina Spirit wasn’t the only winner at Saturday’s Kentucky Derby. Comcast (NASDAQ: CMCSA) subsidiary NBC reported a ratings bonanza for its telecast of the horse racing event.

Medina Spirit wasn’t the only winner at Saturday’s Kentucky Derby. Comcast (NASDAQ:CMCSA) subsidiary NBC reported a ratings bonanza for its telecast of the horse racing event.

What Happened: On Sunday, the NBC Sports PR page on Twitter posted a report that said: “Preliminary figures indicate that NBC’s broadcast of yesterday’s Kentucky Derby will average nearly 15 million viewers – topping all awards shows for the first time ever & marking NBC’s most-watched show since NFL Divisional Playoff in January.”

NBC added that the official Nielsen ratings will be published on May 4. The network's broadcast ran on May 2 ran from 2:30 p.m. EDT through 7:30 p.m. EDT and was also livestreamed on NBCSports.com.

See Also: All About Options Trading with Nic Chahine

Why It Mattered: This weekend’s ratings for the big race was a major bounce back from the 2020 level of 9.8 million, according to Kentucky Sports Radio.

However, last year’s Kentucky Derby was disrupted due to the COVID-19 pandemic, with the race switched from its traditional spot on the first Saturday of May to Sept. 5. And was this not a reflection of the lack of popularity in the event, as viewership on all sports-related television events was down in 2020.

But this weekend’s ratings were also lower than the pre-pandemic Churchill Downs (NYSE:CHDN) perennial in 2019, when the TV ratings were at 16.3 million. The highest-rated telecast of the Kentucky Derby was the 1989 event that brought in a viewing audience of 18.5 million.

(Photo of Medina Spirit in the Kentucky Derby winner’s circle courtesy of the Kentucky National Guard.)

Total
0
Shares
Related Posts
Read More

Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent

Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC's decision with the US Supreme Court.

NVS